Shares of ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.66 and traded as high as $6.89. ImmuCell shares last traded at $6.70, with a volume of 1,783 shares traded.
ImmuCell Stock Up 1.3%
The company has a quick ratio of 2.21, a current ratio of 4.12 and a debt-to-equity ratio of 0.30. The firm has a 50 day moving average of $6.54 and a two-hundred day moving average of $5.66. The firm has a market capitalization of $60.56 million, a price-to-earnings ratio of -95.69 and a beta of 0.32.
ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The company had revenue of $8.07 million for the quarter. ImmuCell had a negative net margin of 1.00% and a negative return on equity of 1.02%.
Institutional Trading of ImmuCell
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares during the last quarter. Dauntless Investment Group LLC acquired a new position in ImmuCell in the 4th quarter worth about $676,000. Northern Trust Corp raised its position in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after purchasing an additional 14,982 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of ImmuCell during the fourth quarter valued at about $149,000. Institutional investors own 13.47% of the company's stock.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
